NATALIE LUFFY: Open Payments
NPI 1730413030 · WEXFORD, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$576 in 25 payments from 11 companies in 2025. Trend: 2023 $946 · 2024 $1,180 · 2025 $576
Food & beverage: $576
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $119 |
| PFIZER INC. | 4 | $84 |
| Novartis Pharmaceuticals Corporation | 3 | $79 |
| UCB, Inc. | 3 | $70 |
| GlaxoSmithKline, LLC. | 2 | $46 |
| Amgen Inc. | 2 | $43 |
| AstraZeneca Pharmaceuticals LP | 2 | $37 |
| Janssen Biotech, Inc. | 1 | $33 |
| Lilly USA, LLC | 1 | $27 |
| E.R. Squibb & Sons, L.L.C. | 1 | $21 |
Products named: SKYRIZI, XELJANZ, COSENTYX, Bimzelx, BENLYSTA, ENBREL, SAPHNELO, TREMFYA.
Industry payments across PA — which companies pay providers there.
